{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:48:35Z","timestamp":1759366115108,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.eimc.2020.10.019","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T18:55:29Z","timestamp":1608144929000},"page":"266-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is there a real risk of bacterial infection in patients receiving targeted and biological therapies?"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-2589","authenticated-orcid":false,"given":"Ivan","family":"Nore\u00f1a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-8001","authenticated-orcid":false,"given":"Mario","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-8255","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2020.10.019_bib0290","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/ibd.21567","article-title":"Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study","volume":"17","author":"Singh","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.eimc.2020.10.019_bib0295","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.cmi.2018.01.029","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of targeted and biological therapies: an Infectious Diseases perspective (Introduction)","volume":"24","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 2","key":"10.1016\/j.eimc.2020.10.019_bib0300","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents)","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 2","key":"10.1016\/j.eimc.2020.10.019_bib0305","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 2","key":"10.1016\/j.eimc.2020.10.019_bib0310","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.cmi.2017.12.027","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Cell surface receptors and associated signaling pathways)","volume":"24","author":"Aguilar-Company","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 2","key":"10.1016\/j.eimc.2020.10.019_bib0315","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 2","key":"10.1016\/j.eimc.2020.10.019_bib0320","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 2","key":"10.1016\/j.eimc.2020.10.019_bib0325","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 2","key":"10.1016\/j.eimc.2020.10.019_bib0330","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","volume":"24","author":"Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2020.10.019_bib0335","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.eimc.2020.10.019_bib0340","first-page":"287","article-title":"management of infections in rheumatic patients receiving biological therapies. The Portuguese Society of rheumatology recommendations","volume":"2016","author":"Teixeira","year":"2016","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.eimc.2020.10.019_bib0345","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/acr.22281","article-title":"risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis","volume":"66","author":"Curtis","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.eimc.2020.10.019_bib0350","first-page":"60","article-title":"Risk of hospitalization for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the record study of the Italian society for rheumatology","volume":"37","author":"Carrara","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0179179","article-title":"Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: a multicenter retrospective cohort study in Japan","volume":"12","author":"Mori","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.eimc.2020.10.019_bib0360","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2020.10.019_bib0365","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0370","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.eimc.2020.10.019_bib0375","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.eimc.2020.10.019_bib0380","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2004.033662","article-title":"Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice","volume":"65","author":"Den Broeder","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.eimc.2020.10.019_bib0385","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.eimc.2020.10.019_bib0390","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.eimc.2020.10.019_bib0395","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/rheumatology\/kev372","article-title":"ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany","volume":"55","author":"Iking-Konert","year":"2016","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.eimc.2020.10.019_bib0400","doi-asserted-by":"crossref","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.eimc.2020.10.019_bib0405","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0410","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"Van De Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0415","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from 7 clinical trials of Ixekizumab an anti-interleukin-17A monoclonal antibody in patients with moderate-to-severe psoriasis","volume":"167","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0420","first-page":"961","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatology","volume":"151","author":"Kalb","year":"2015"},{"key":"10.1016\/j.eimc.2020.10.019_bib0425","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.critrevonc.2015.02.007","article-title":"Bevacizumab increases the risk of infections in cancer patients: a systematic review and pooled analysis of 41 randomized controlled trials","volume":"94","author":"Qi","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0430","doi-asserted-by":"crossref","first-page":"E461","DOI":"10.3390\/ijms18020461","article-title":"Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma","volume":"18","author":"Hansen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eimc.2020.10.019_bib0435","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2020.10.019_bib0440","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","article-title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0445","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.ctrv.2014.09.002","article-title":"Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis","volume":"40","author":"Funakoshi","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eimc.2020.10.019_bib0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0203-5","article-title":"Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis","volume":"12","author":"Qi","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.eimc.2020.10.019_bib0455","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10549-014-3184-3","article-title":"Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis","volume":"149","author":"Funakoshi","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.eimc.2020.10.019_bib0460","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2020.10.019_bib0465","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2020.10.019_bib0470","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.eimc.2020.10.019_bib0475","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/07357907.2016.1242009","article-title":"Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer","volume":"34","author":"Garcia","year":"2016","journal-title":"Cancer Invest"},{"key":"10.1016\/j.eimc.2020.10.019_bib0480","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2020.10.019_bib0485","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/cncr.30031","article-title":"Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies","volume":"122","author":"Kantarjian","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.eimc.2020.10.019_bib0490","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.eimc.2020.10.019_bib0500","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1741-7015-9-36","article-title":"Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis","volume":"9","author":"Lanini","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.eimc.2020.10.019_bib0505","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: Final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"Van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0510","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/jth.13622","article-title":"Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect","volume":"15","author":"Moulis","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.eimc.2020.10.019_bib0515","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab","volume":"132","author":"Thursky","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0520","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0525","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/14740338.2016.1248402","article-title":"The safety of anti PD-1 therapeutics for the treatment of melanoma","volume":"16","author":"Ramelyte","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.eimc.2020.10.019_bib0530","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2020.10.019_bib0535","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2020.10.019_bib0540","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2020.10.019_bib0545","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.14075","article-title":"Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease","volume":"46","author":"Bye","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eimc.2020.10.019_bib0550","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): and randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0555","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eimc.2020.10.019_bib0560","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/cid\/ciu938","article-title":"Asymptomatic bacteriuria in women with autoimmune rheumatic disease: prevalence, risk factors, and clinical significance","volume":"60","author":"Georgiadou","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2020.10.019_bib0565","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1473-3099(15)00070-5","article-title":"Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial","volume":"15","author":"Kazemier","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimc.2020.10.019_bib0570","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1111\/ajt.13829","article-title":"Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients? Results from a randomized controlled trial","volume":"16","author":"Orig\u00fcen","year":"2016","journal-title":"Am J Transplant"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20303980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20303980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:07:35Z","timestamp":1759324055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X20303980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0213005X20303980"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2020.10.019","relation":{},"ISSN":["0213-005X"],"issn-type":[{"type":"print","value":"0213-005X"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there a real risk of bacterial infection in patients receiving targeted and biological therapies?","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2020.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}